Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis

• DOI: 10.1007/s10096-011-1367-y
• Publication Date: 2011-08-06T11:08:13Z
• Authors: F. Campanile; D. Bongiorno; M. Falcone; F. Vailati; M. B. Pasticci; M. Perez; A. Raglio; F. Rumpianesi; C. Scuderi; F. Suter; M. Venditti; C. Venturelli; V. Ravasio; M. Codeluppi; S. Stefani
• Keywords: Microbiology (medical); 0301 basic medicine; Cross Infection; Staphylococcus aureus; Genotype; Bacteremia; Vancomycin Resistance; Endocarditis, Bacterial; Microbial Sensitivity Tests; Staphylococcal Infections; Article; Anti-Bacterial Agents; 3. Good health; Molecular Typing; 03 medical and health sciences; Infectious Diseases; Italy; Cluster Analysis; Humans

Bloodstream infections due to Staphylococcus aureus (BSI) are serious infections both in hospitals and in the community, possibly leading to infective endocarditis (IE). The use of glycopeptides has been recently challenged by various forms of low-level resistance. This study evaluated the distribution of MSSA and MRSA isolates from BSI and IE in 4 Italian hospitals, their antibiotic susceptibility--focusing on the emergence of hVISA--and genotypic relationships. Our results demonstrate that the epidemiology of MRSA is changing versus different STs possessing features between community-acquired (CA)- and hospital-acquired (HA)-MRSA groups; furthermore, different MSSA isolated from BSI and IE were found, with the same backgrounds of the Italian CA-MRSA. The hVISA phenotype was very frequent (19.5%) and occurred more frequently in isolates from IE and in both the MSSA and MRSA strains. As expected, hVISA were detected in MRSA with vancomycin minimum inhibitory concentrations (MICs) of 1-2 mg/l, frequently associated with the major SCCmec I and II nosocomial clones; this phenotype was also detected in some MSSA strains. The few cases of MR-hVISA infections evaluated in our study demonstrated that 5 out of 9 patients (55%) receiving a glycopeptide, died. Future studies are required to validate these findings in terms of clinical impact.